Gene silencing of myofibrillogenesis regulator-1 by adenovirus-delivered small interfering RNA suppresses cardiac hypertrophy induced by angiotensin II in mice

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 299, Issue 5, 2010, Pages

  Dai, Wenjian ^a,b   He, Weiqing ^a   Shang, Guangdong ^c   Jiang, Jiandong ^a   Wang, Yiguang ^a   Kong, Weijia ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^b Hunan Environment Biological Polytechnic   (China)

^c NANJING NORMAL UNIVERSITY   (China)

Author keywords

RNA interference

Indexed keywords

ADENOVIRUS VECTOR; ANGIOTENSIN II; MESSENGER RNA; MYOFIBRILLOGENESIS REGULATOR 1 PROTEIN; REGULATOR PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRUS DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE SILENCING; HEART HYPERTROPHY; HEART MUSCLE FIBROSIS; HUMAN; HUMAN CELL; INFLAMMATORY INFILTRATE; KIDNEY; LIVER; LUNG; MALE; MOUSE; MYOCARDITIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATOR GENE; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANGIOTENSIN II; ANIMALS; CARDIOMEGALY; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX; GENE SILENCING; GENE TRANSFER TECHNIQUES; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED C57BL; MUSCLE PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 78249248971     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00582.2009     Document Type: Article

References (37)

1. Baltzer AW, Lattermann C, Whalen JD, Wooley P, Weiss K, Grimm M, Ghivizzani SC, Robbins PD, Evans CH. Genetic enhancement of fracture repair: healing of an experimental segmental defect by adenoviral transfer of the BMP-2 gene. Gene Ther 7: 734-739, 2000. (Pubitemid 30255754)
2. Berenji K, Drazner MH, Rothermel BA, Hill JA. Does load-induced ventricular hypertrophy progress to systolic heart failure? Am J Physiol Heart Circ Physiol 289: H8-H16, 2005.
3. Brilla CG. Renin-angiotensin-aldosterone system and myocardial fibrosis. Cardiovasc Res 47: 1-3, 2000.
4. Clemente CF, Tornatore TF, Theizen TH, Deckmann AC, Pereira TC, Lopes-Cendes I, Souza JR, Franchini KG. Targeting focal adhesion kinase with small interfering RNA prevents and reverses load-induced cardiac hypertrophy in mice. Circ Res 101: 1339-1348, 2007. (Pubitemid 350294651)
5. Collins AR, Schnee J, Wang W, Kim S, Fishbein MC, Bruemmer D, Law RE, Nicholas S, Ross RS, Hsueh WA. Osteopontin modulates angiotensin II-induced fibrosis in the intact murine heart. J Am Coll Cardiol 43: 1698-1705, 2004. (Pubitemid 38561355)
6. Díez J. Emerging role of matrix metalloproteinases in the pathophysiology of cardiac diseases. Eur J Clin Invest 32: 291-294, 2002. (Pubitemid 36228386)
7. Dobrzynski E, Wang C, Chao J, Chao L. Adrenomedullin gene delivery attenuates hypertension, cardiac remodeling, and renal injury in deoxycorticosterone acetate-salt hypertensive rats. Hypertension 36: 995-1001, 2000.
8. Drazner MH, Rame JE, Marino EK, Gottdiener JS, Kitzman DW, Gardin JM, Manolio TA, Dries DL, Siscovick DS. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health study. J Am Coll Cardiol 43: 2207-2215, 2004.
9. Fasbender A, Zabner J, Chillón M, Moninger TO, Puga AP, Davidson BL, Welsh MJ. Complexes of adenovirus with polycationic polymers and cationic lipids increase the efficiency of gene transfer in vitro and in vivo. J Biol Chem 272: 6479-6489, 1997. (Pubitemid 27118128)
10. Frantz S, Fraccarollo D, Wagner H, Behr TM, Jung P, Angermann CE, Ertl G, Bauersachs J. Sustained activation of nuclear factor κB and activator protein 1 in chronic heart failure. Cardiovasc Res 57: 749-756, 2003. (Pubitemid 36254868)
11. Friddle CJ, Koga T, Rubin EM, Bristow J. Expression profiling reveals distinct sets of genes altered during induction and regression of cardiac hypertrophy. Proc Natl Acad Sci USA 97: 6745-6750, 2000. (Pubitemid 30412785)
12. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95: 2509-2514, 1998. (Pubitemid 28145972)
13. Hijova E. Matrix metalloproteinases: their biological functions and clinical implications. Bratisl Lek Listy 106: 127-132, 2005.
14. Horio T, Nishikimi T, Yoshihara F, Matsuo H, Takishita S, Kangawa K. Effects of adrenomedullin on cultured rat cardiac myocytes and fibroblasts. Eur J Pharmacol 382: 1-9, 1999.
15. Hwang DM, Dempsey AA, Lee CY, Liew CC. Identification of differentially expressed genes in cardiac hypertrophy by analysis of expressed sequence tags. Genomics 66: 1-14, 2000.
16. Ichihara S, Senbonmatsu T, Price E Jr, Ichiki T, Gaffney FA, Inagami T. Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. Circulation 104: 346-351, 2001.
17. Ju H, Dixon IM. Effect of angiotensin II on myocardial collagen gene expression. Mol Cell Biochem 163-164: 231-237, 1996.
18. Kim S, Ohta K, Hamaguchi A, Yukimura T, Miura K, Iwao H. Angiotensin II induces cardiac phenotypic modulation and remodeling in vivo in rats. Hypertension 25: 1252-1259, 1995.
19. Kim-Mitsuyama S, Izumi Y, Izumiya Y, Namba M, Yoshida K, Wake R, Yoshiyama M, Iwao H. Dominant-negative c-Jun inhibits rat cardiac hypertrophy induced by angiotensin II and hypertension. Gene Ther 13: 348-355, 2006.
20. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart study. N Engl J Med 322: 1561-1566, 1990.
21. Li HL, She ZG, Li TB, Wang AB, Yang Q, Wei YS, Wang YG, Liu DP. Overexpression of myofibrillogenesis regulator-1 aggravates cardiac hypertrophy induced by angiotensin II in mice. Hypertension 49: 1399-1408, 2007.
22. Li TB, Hu Y, Feng S, Zuo ZY, Wang YG. Expression of a human myofibrillogenesis regulator 1 gene in E. coli and its immunogenicity. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 27: 42-47, 2005.
23. Li TB, Liu XH, Feng S, Hu Y, Yang WX, Han Y, Wang YG, Gong LM. Characterization of MR-1, a novel myofibrillogenesis regulator in human muscle. Acta Biochim Biophys Sin (Shanghai) 36: 412-418, 2004.
24. Liu X, Li T, Sun S, Xu F, Wang Y. Role of myofibrillogenesis regulator-1 in myocardial hypertrophy. Am J Physiol Heart Circ Physiol 290: H279-H285, 2006.
25. Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 102: 470-479, 2000.
26. Luedde M, Katus HA, Frey N. Novel molecular targets in the treatment of cardiac hypertrophy. Recent Patents Cardiovasc Drug Discov 1: 1-20, 2006.
27. Miyajima E, Shigemasa T, Endo T, Hishiki S, Kawano Y. Guanabenz combination therapy inhibits sympathetic nerve activity and regresses left ventricular hypertrophy. Cardiovasc Drugs Ther 14: 61-66, 2000.
28. Niu J, Azfer A, Deucher MF, Goldschmidt-Clermont PJ, Kolattukudy PE. Targeted cardiac expression of soluble Fas prevents the development of heart failure in mice with cardiac-specific expression of MCP-1. J Mol Cell Cardiol 40: 810-820, 2006.
29. Onai Y, Suzuki J, Maejima Y, Haraguchi G, Muto S, Itai A, Isobe M. Inhibition of NF-κB improves left ventricular remodeling and cardiac dysfunction after myocardial infarction. Am J Physiol Heart Circ Physiol 292: H530-H538, 2007.
30. Pachori AS, Numan MT, Ferrario CM, Diz DM, Raizada MK, Katovich MJ. Blood pressure-independent attenuation of cardiac hypertrophy by AT1R-AS gene therapy. Hypertension 39: 969-975, 2002.
31. Sandovici M, Deelman LE, Smit-van Oosten A, van Goor H, Rots MG, de Zeeuw D, Henning RH. Enhanced transduction of fibroblasts in transplanted kidney with an adenovirus having an RGD motif in the HI loop. Kidney Int 69: 45-52, 2006.
32. Shiomi T, Tsutsui H, Ikeuchi M, Matsusaka H, Hayashidani S, Suematsu N, Wen J, Kubota T, Takeshita A. Streptozotocin-induced hyperglycemia exacerbates left ventricular remodeling and failure after experimental myocardial infarction. J Am Coll Cardiol 42: 165-172, 2003. (Pubitemid 36760779)
33. Thirion C, Lochmüller H, Ruzsics Z, Boelhauve M, König C, Thedieck C, Kutik S, Geiger C, Kochanek S, Volpers C, Burgert HG. Adenovirus vectors based on human adenovirus type 19a have high potential for human muscle-directed gene therapy. Hum Gene Ther 17: 193-205, 2006.
34. Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 94: 3352-3356, 1997.
35. Wang C, Dobrzynski E, Chao J, Chao L. Adrenomedullin gene delivery attenuates renal damage and cardiac hypertrophy in Goldblatt hypertensive rats. Am J Physiol Renal Physiol 280: F964-F971, 2001.
36. Wang M, Zhang J, Spinetti G, Jiang LQ, Monticone R, Zhao D, Cheng L, Krawczyk M, Talan M, Pintus G, Lakatta EG. Angiotensin II activates matrix metalloproteinase type II and mimics age-associated carotid arterial remodeling in young rats. Am J Pathol 167: 1429-1442, 2005.
37. Xia H, Mao Q, Paulson HL, Davidson BL. siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 20: 1006-1010, 2002.